Eppendorf Award for Young European Investigators

Applications are invited for the 2008 Eppendorf Award for Young European
Investigators, presented by Eppendorf AG in partnership with the scientific journal Nature.
Open to scientists no older than 35 years of age, the €15,000 prize is intended to encourage and support the work of promising European biomedical researchers.
According to Jörn Peplow, Eppendorf Corporate Communications, ‘This prestigious prize was established in 1995 to celebrate Eppendorf’s 50th anniversary, symbolising the close links between the company and the
field of biomedicine. The criteria on which entries are evaluated include creativity, the ability to work independently, the significance
of research results for the field of medicine and the successful practical application of the research approach.’
Applications for The Eppendorf Award for Young European Investigators 2008, which must be submitted online at eppendorf.com/award by 30 June, need to include a short CV, a list of publications, a maximum of three papers to be evaluated and a 300-word essay summarising the papers. The 2008 prize-winner will be selected by a completely independent
committee chaired by Professor Kai Simons, Managing Director of the Max Plank Institute for Molecular Cell Biology and Genetics, Dresden, Germany. Eppendorf will provide full support for the winner to attend the award presentation on 20 November 2008 at the Medica Congress in Düsseldorf, Germany.
The 2007 award was won by Dr Mónica Bettencourt-Dias, a group leader at the Instituto Gulbenkian de Ciência in Oerias, Portugal. Her pioneering research on centrosome biogenesis opens up new avenues for understanding cell cycle control and for cancer therapy.
Eppendorf UK, headquartered in Cambridge, is a subsidiary of Eppendorf AG, Hamburg, Germany, a leading global supplier of systems and research tools for the biotechnology industry. With over 1800 employees on four
continents, Eppendorf AG achieved a turnover of £224m (€320.9m) in 2005 and operating profits (EBIT) of £35m (€50.4m).